(NASDAQ: IMCR) Immunocore Holdings's forecast annual revenue growth rate of 10.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.86%.
Immunocore Holdings's revenue in 2025 is $379,590,000.On average, 19 Wall Street analysts forecast IMCR's revenue for 2025 to be $20,739,705,174, with the lowest IMCR revenue forecast at $19,723,538,448, and the highest IMCR revenue forecast at $21,674,012,622. On average, 19 Wall Street analysts forecast IMCR's revenue for 2026 to be $22,917,060,929, with the lowest IMCR revenue forecast at $20,669,467,892, and the highest IMCR revenue forecast at $25,081,784,079.
In 2027, IMCR is forecast to generate $26,051,968,124 in revenue, with the lowest revenue forecast at $19,110,099,162 and the highest revenue forecast at $31,447,100,960.